St. Boniface Hospital

The trials here

What the 21 trials at this site are about, from their registry records.

Conditions

• Heart failure7 trials
• Coronary artery disease6 trials
• Deep vein thrombosis and pulmonary embolism2 trials
• Hypertrophic cardiomyopathy2 trials
• Obesity2 trials
• Stroke2 trials
• Aortic stenosis1 trial
• Atrial fibrillation1 trial
• Chronic kidney disease1 trial
• Coeliac disease1 trial
• High blood pressure1 trial

Phase

• Phase 38 trials
• Phase 23 trials
• Phase 42 trials
• Phase 2/31 trial

Status

• Completed6 trials
• Recruiting6 trials
• Active, not recruiting4 trials
• Not yet recruiting4 trials
• Terminated1 trial

Lead sponsor

• Cytokinetics2 trials
• Montreal Heart Institute2 trials
• University of Calgary2 trials
• University of Manitoba2 trials
• Abiomed Inc.1 trial
• and 12 more

Running trials

• Recruiting

  A Phase 2b Clinical Trial of YN001 in Adults With Coronary Atherosclerosis

  NCT07521007· Phase 2· Beijing Inno Medicine Co., Ltd.· Source

  Contact: Shuangbo Liu

• Recruiting

  A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity

  NCT07567001· Phase 3· Novo Nordisk A/S· Source

  Contact: Novo Nordisk

• Not yet recruiting

  Tailoring Post Discharge - Remote Education and Access for Cardiac Health

  NCT07171580· St. Boniface Hospital· Source

  Contact: Shuangbo Liu, MD

• Recruiting

  Ataciguat for Slowing the Progression of Moderate Calcific Aortic Valve Stenosis: A Randomized, Placebo Controlled Study

  NCT07001800· Phase 2/3· Kardigan, Inc.· Source

• Recruiting

  Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

  NCT07037459· Phase 3· Amgen· Source

• Recruiting

  Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction

  NCT06736574· Phase 3· Cytokinetics· Source

  Contact: Cytokinetics MD

• Recruiting

  The STOP-MED CTRCD Trial

  NCT06183437· Phase 4· Dinesh Thavendiranathan· Source

  Contact: Davinder Jassal, MD

• Active, not recruiting

  Phosphatase Inhibition by Intracoronary Gene Therapy in Subjects With Non-Ischemic NYHA Class III Heart Failure

  NCT05598333· Phase 2· AskBio Inc· Source

• Active, not recruiting

  A Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)

  NCT06081894· Phase 3· Cytokinetics· Source

• Active, not recruiting

  Physiology-guided vs Angiography-guided Non-culprit Lesion Complete Revascularization for Acute MI & Multivessel Disease

  NCT05701358· Population Health Research Institute· Source

• Recruiting

  PRospective Evaluation of Peripartum Anticoagulation ManaGement for ThrOmboembolism

  NCT05756244· University of Calgary· Source

  Contact: David Kent

• Recruiting

  CKD Specific Telemonitoring Platform to Minimize Adverse Outcomes in High Risk CKD Patients

  NCT05726526· University of Manitoba· Source

  Contact: Reid Whitlock, MSc

• Active, not recruiting

  Impella®-Supported PCI in High-Risk Patients With Complex Coronary Artery Disease and Reduced Left Ventricular Function

  NCT04763200· Abiomed Inc.· Source

• Recruiting

  Hypertrophic Cardiomyopathy Registry, Biobank and Imaging Data Repository

  NCT05100420· Montreal Heart Institute· Source

  Contact: Colette Seifer, MD (principal investigator)

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Heart failure4 recruiting
• Coronary artery disease2 recruiting
• Obesity2 recruiting
• Aortic stenosis1 recruiting
• Chronic kidney disease1 recruiting
• Deep vein thrombosis and pulmonary embolism1 recruiting
• Hypertrophic cardiomyopathy1 recruiting

Closed trials

• Completed

  A Trial of a Hospital Policy of Tranexamic Acid Use to Reduce Transfusion in Major Non-cardiac Surgery

  NCT04803747· Phase 4· University of Manitoba· Source

• Completed

  EMPACT-MI: A Study to Test Whether Empagliflozin Can Lower the Risk of Heart Failure and Death in People Who Had a Heart Attack (Myocardial Infarction)

  NCT04509674· Phase 3· Boehringer Ingelheim· Source

• Completed

  Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40%

  NCT04435626· Phase 3· Bayer· Source

• Completed

  A Randomized, Double-Blind, Placebo Controlled, Crossover Trial to Evaluate Safety and Efficacy of AGY in Celiac Disease

  NCT03707730· Phase 2· Igy Inc.· Source

• Terminated

  Blinded Randomized Trial of Anticoagulation to Prevent Ischemic Stroke and Neurocognitive Impairment in AF

  NCT02387229· Phase 3· Montreal Heart Institute· Source

• Completed

  Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial

  NCT02089217· Mayo Clinic· Source

• Completed

  Efficacy of Implantable Defibrillator Therapy After a Myocardial Infarction

  NCT00673842· Phase 3· University of Calgary· Source